All eyes are on ABcann Medicinals, Inc. as it prepares to go public. The company, which is already growing rapidly, wants to expand its footprint in Canada and take advantage of potential international opportunities.
All eyes are on ABcann Medicinals, Inc. as it prepares to go public. The company, which is already growing rapidly, wants to expand its footprint in Canada and take advantage of potential international opportunities.
According to efficient markets theory, the chances of finding hundred-dollar bills lying on the ground are slim, at best. When one is dropped, some well-informed investor is quick to pick it up.
Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced its appointment of Summer (XiangYang) Yun as chief executive officer of its CBD Biotechnology Co., Ltd. subsidiary, which it originally launched in March of this year.
Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning offered investors an update on its financial and business achievements for the fiscal third quarter ended February 28, 2017, as well as its outlook for the remainder of the current fiscal year and 2018.
Forget everything you’ve heard up to now about marijuana stocks, a recent survey reveals the best reason to invest in marijuana today.
Courtesy of Ted Chung Snoop Dogg With the legal cannabis industry generating $6.9 billion in sales in 2016, up 34% from 2015, it’s a no-brainer to say that much is at stake as the business inevitably grows. Much like the independent movie biz, the cannabis industry attracts investors looking for high-risk, high-reward investments, and as marijuana goes more mainstream, so does the funding mechanisms for the industry’s businesses.
Medical marijuana companies will likely tap the Canadian bond market to fund growth as investors become more comfortable with the industry and the federal government gets set to legalize the drug by next year.
“There would be an appetite for more traditional debt arrangements and, given that leading cannabis companies have significant assets now, this may be one direction that we see the market go in the future,” said Cam Battley, executive vice president of Aurora Cannabis Inc., a licensed marijuana producer in Mountain View County, Alberta. “I suspect we’re headed in that direction right now.”
India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that it has filed patent applications for IGC-501 in Canada, Israel and Europe in support of its ongoing cannabis-based combination therapy development initiatives.
Saturday, April 8, 2017
Bipartisan legislation proposed in the House on Thursday would make marijuana a Schedule 3 drug, removing cannabis from its current standing as a Schedule 1 substance alongside deadly contraband including ecstasy and heroin.
By reclassifying weed in the same category as anabolic steroids, Congress would “make it easier for ill-patients and scientific and medical researchers to obtain marijuana,” the bill’s authors said in a statement Thursday.
A pre-clinical stage biopharmaceutical company, InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) has revealed two additions to its drug development pipeline.
India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced the sale of its investment interest in Brilliant Hallmark for a consideration of four million shares of IGC.
ChineseInvestors.com, Inc. (OTCQB: CIIX) is planning to open a retail store in San Gabriel, California, the same city in which the company is headquartered.
India Globalization Capital CEO Ram Mukunda discusses his company's operations and targeted market, as well as leading formulations it is currently working on.
Advancements continue to be made in various CBD extractions as the demand for cannabis extracts continues to climb at a high rate. Cannabidiol (CBD) is one of the most important healing substances, with a strong anti-inflammatory effect and without a psychotropic (narcotic) effect.
Canaccord Genuity analyst Neil Maruoka thinks Canopy Growth Corp. (TSX:WEED) is the “dominant player” in the Canadian cannabis sector, but says the company’s stock is fully valued at current levels.